Retatrutide vs Tirzepatide: Comparing Two Weight Loss Medications

If you've been following developments in weight loss medication, you've likely heard about Tirzepatide—the dual-action medication that's been making waves. But there's a newer player emerging: Retatrutide. While Tirzepatide is already changing lives, Retatrutide is showing even more promising results in clinical trials. Let's break down how these two medications compare and what that means for your health journey.

What Is Tirzepatide?

Tirzepatide is an FDA-approved medication that works on two hormone pathways in your body. It mimics both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, which is why it's called a dual agonist.

This medication helps regulate blood sugar, slows digestion, and reduces appetite. It's approved for type 2 diabetes under the brand name Mounjaro and for weight management as Zepbound. Clinical trials showed that people lost an average of 15-22% of their body weight over 72 weeks.

Tirzepatide has been available since 2022, which means we have real-world experience with how it works for diverse populations over time.

What Is Retatrutide?

Retatrutide takes things a step further. It's a triple agonist, meaning it activates three hormone receptors: GLP-1, GIP, and glucagon. By adding glucagon into the mix, Retatrutide may increase energy expenditure and fat burning in ways that dual agonists don't.

As of now, Retatrutide is still in clinical trials and hasn't received FDA approval yet. However, the early results are impressive—some trial participants lost up to 24% of their body weight in 48 weeks, which is notably higher than what we typically see with other medications.

The additional glucagon activity might also offer benefits for liver health and metabolism, though more research is needed to fully understand these effects.

How They Compare: Effectiveness

Both medications produce significant weight loss, but Retatrutide appears to edge ahead in clinical trials.

In head-to-head comparisons of trial data, Retatrutide participants lost slightly more weight on average. The triple-action mechanism seems to provide an extra metabolic boost that the dual-action approach doesn't quite match.

That said, Tirzepatide's results are already remarkable, and it has the advantage of being proven in real-world settings with millions of patients. Sometimes what looks better in controlled trials doesn't always translate the same way in everyday life.

Both medications also improve metabolic markers like blood sugar, cholesterol, and blood pressure—benefits that extend well beyond the number on the scale.

Side Effects: What to Expect

Because both medications work on similar pathways, they share many of the same side effects.

The most common issues with both are digestive: nausea, diarrhea, constipation, and occasional vomiting. These symptoms tend to be worst when starting the medication or increasing doses, and they typically improve over time as your body adjusts.

With Retatrutide's added glucagon activity, there's some concern about slightly higher rates of nausea in early trials, though this hasn't been definitively established yet. The glucagon component could theoretically affect heart rate as well, which researchers are monitoring closely.

Both medications carry similar warnings about thyroid tumors (based on rodent studies), pancreatitis risk, and gallbladder issues. Neither should be used if you have a personal or family history of medullary thyroid carcinoma.

Gender Considerations

Women may experience side effects somewhat differently than men, particularly nausea and digestive issues. Hormonal fluctuations during menstrual cycles can sometimes amplify these symptoms. Both medications should be discontinued if pregnancy is planned, as safety data in pregnancy is limited. Men in trials reported slightly fewer gastrointestinal side effects overall, though individual experiences vary widely regardless of gender.

Availability and Cost

This is where the comparison becomes very practical.

Tirzepatide is FDA-approved and available now through prescription. You can get the brand-name versions or compounded versions through telehealth providers. Insurance coverage varies, but compounded options have made it more accessible for many people.

Retatrutide isn't available yet outside of clinical trials. It's likely still a few years away from FDA approval, and even then, it will probably launch at a premium price point as a brand-new medication. There won't be compounded versions available initially.

If you're looking for treatment now, Tirzepatide is your option. If you're willing to wait and see how Retatrutide develops, that might be worth considering down the road.

Which One Is Right for You?

Since Retatrutide isn't yet available, the practical choice right now is Tirzepatide if you're considering this class of medication.

Tirzepatide has a proven track record with excellent results for both weight loss and metabolic health. It's being prescribed by thousands of physicians and used successfully by real patients every day.

When Retatrutide does become available, it might be worth discussing with your doctor if you haven't achieved your goals with other medications, or if the additional mechanism offers specific benefits for your situation.

The best medication is always the one that works for your body, your lifestyle, and your health goals. That's a conversation to have with a qualified healthcare provider who knows your complete medical history.

From the Ozari Care Team

Both of these medications can cause significant gastrointestinal side effects when you first start or increase your dose. Our best advice: eat smaller portions, choose less fatty foods, and stay well-hydrated during the adjustment period. Most patients find these side effects improve substantially after the first few weeks, but listening to your body and adjusting your eating habits makes a real difference in your comfort level.

At Ozari Health we offer compounded Semaglutide and Tirzepatide as low as $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically Reviewed — Ozari Clinical Content Team (OCCT). Health writers and wellness professionals specializing in GLP-1 therapy, metabolic health, and weight loss medicine. Content reviewed in accordance with Ozari's Editorial Standards. Last reviewed: April 25, 2026.

This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

Last reviewed: April 25, 2026